Drug-loaded nanoparticle systems and adult stem cells: A potential marriage for the treatment of malignant glioma?

Oncotarget

Volumn 4, Issue 3, 2013, Pages 378-396

  Auffinger, Brenda ^a   Morshed, Ramin ^a   Tobias, Alex ^a   Cheng, Yu ^a   Ahmed, Atique U ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Brain cancer; Drug delivery systems; Malignant glioma; Nanoparticle; Stem cell carriers; Targeted delivery

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; APO2 LIGAND TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; BLEOMYCIN; CYTOSINE DEAMINASE; DENDRIMER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR VIII ANTIBODY; FERROCIPHENOL; FLUCYTOSINE; GOLD NANOPARTICLE; INTERLEUKIN 13 RECEPTOR ALPHA2 ANTIBODY; LIGAND; LIPOSOME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD133; NANOPARTICLE; NANOPLATFORM; PHENOL DERIVATIVE; POLYETHYLENEIMINE; POLYMERIC NANOPARTICLE; REACTIVE OXYGEN METABOLITE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRANSFERRIN LIGAND; UNCLASSIFIED DRUG; VASCULOTROPIN; VINCRISTINE;

ADULT STEM CELL; ARTICLE; BLOOD BRAIN BARRIER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURGERY; CARDIOTOXICITY; CONVECTION ENHANCED DELIVERY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; ENHANCED PERMEABILITY AND RETENTION EFFECT; GLIOBLASTOMA; HUMAN; HYPERTHERMIC THERAPY; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LIGAND BINDING; LOCAL THERAPY; MESENCHYMAL STEM CELL; MICELLE; NEURAL STEM CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; PARTICLE SIZE; STEM CELL TRANSPLANTATION; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; SYSTEMIC THERAPY;

EID: 84879012409     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.937     Document Type: Article

References (158)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352(10):987-996.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The lancet oncology. 2009; 10(5):459-466.
3. Pardridge WM. Molecular biology of the blood-brain barrier. Molecular biotechnology. 2005; 30(1):57-70.
4. Beier D, Schulz JB and Beier CP. Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Molecular cancer. 2011; 10:128.
5. Kumagai AK, Eisenberg JB and Pardridge WM. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. The Journal of biological chemistry. 1987; 262(31):15214-15219.
6. Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ and Kreuter J. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. Journal of drug targeting. 2006; 14(2):97-105.
7. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. Journal of nanoscience and nanotechnology. 2004; 4(5):484-488.
8. Ambasta RK, Sharma A and Kumar P. Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vascular cell. 2011; 3:26.
9. Klibanov AL, Maruyama K, Torchilin VP and Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS letters. 1990; 268(1):235-237.
10. Pardridge WM. Recent developments in peptide drug delivery to the brain. Pharmacology & toxicology. 1992;71(1):3-10.
11. Ahmed AU, Tyler MA, Thaci B, Alexiades NG, Han Y, Ulasov IV and Lesniak MS. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Molecular pharmaceutics. 2011; 8(5):1559-1572.
12. Ahmed AU and Lesniak MS. Glioblastoma multiforme: can neural stem cells deliver the therapeutic payload and fulfill the clinical promise? Expert review of neurotherapeutics. 2011; 11(6):775-777.
13. Ahmed AU, Thaci B, Alexiades NG, Han Y, Qian S, Liu F, Balyasnikova IV, Ulasov IY, Aboody KS and Lesniak MS. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Molecular therapy : the journal of the American Society of Gene Therapy. 2011; 19(9):1714-1726.
14. Lorenz MR, Holzapfel V, Musyanovych A, Nothelfer K, Walther P, Frank H, Landfester K, Schrezenmeier H and Mailander V. Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials. 2006; 27(14):2820-2828.
15. Ryan JM, Barry FP, Murphy JM and Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005; 2:8.
16. Alexis F, Pridgen EM, Langer R and Farokhzad OC. Nanoparticle technologies for cancer therapy. Handbook of experimental pharmacology. 2010; (197):55-86.
17. Kim BY, Rutka JT and Chan WC. Nanomedicine. The New England journal of medicine. 2010; 363(25):2434-2443.
18. Dobson J. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene therapy. 2006; 13(4):283-287.
19. Xia Y, Xiong Y, Lim B and Skrabalak SE. Shape-controlled synthesis of metal nanocrystals: simple chemistry meets complex physics? Angewandte Chemie. 2009; 48(1):60-103.
20. Torchilin VP. Multifunctional nanocarriers. Advanced drug delivery reviews. 2006; 58(14):1532-1555.
21. Mohs AM and Provenzale JM. Applications of nanotechnology to imaging and therapy of brain tumors. Neuroimaging clinics of North America. 2010; 20(3):283-292.
22. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature reviews Drug discovery. 2005; 4(2):145-160.
23. Caruso G, Caffo M, Alafaci C, Raudino G, Cafarella D, Lucerna S, Salpietro FM and Tomasello F. Could nanoparticle systems have a role in the treatment of cerebral gliomas? Nanomedicine : nanotechnology, biology, and medicine. 2011; 7(6):744-752.
24. Aliabadi HM, Shahin M, Brocks DR and Lavasanifar A. Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery. Clinical pharmacokinetics. 2008; 47(10):619-634.
25. Liu L, Venkatraman SS, Yang YY, Guo K, Lu J, He B, Moochhala S and Kan L. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. Biopolymers. 2008; 90(5):617-623.
26. Sethuraman VA, Lee MC and Bae YH. A biodegradable pH-sensitive micelle system for targeting acidic solid tumors. Pharmaceutical research. 2008; 25(3):657-666.
27. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R and Farokhzad OC. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(7):2586-2591.
28. Langer R and Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976; 263(5580):797-800.
29. Lee CC, MacKay JA, Frechet JM and Szoka FC. Designing dendrimers for biological applications. Nature biotechnology. 2005; 23(12):1517-1526.
30. Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L and Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chemical reviews. 2008; 108(6):2064-2110.
31. Sun C, Veiseh O, Gunn J, Fang C, Hansen S, Lee D, Sze R, Ellenbogen RG, Olson J and Zhang M. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small. 2008; 4(3):372-379.
32. Silva AC, Oliveira TR, Mamani JB, Malheiros SM, Malavolta L, Pavon LF, Sibov TT, Amaro E, Jr., Tannus A, Vidoto EL, Martins MJ, Santos RS and Gamarra LF. Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment. International journal of nanomedicine. 2011; 6:591-603.
33. Ghosh P, Han G, De M, Kim CK and Rotello VM. Gold nanoparticles in delivery applications. Advanced drug delivery reviews. 2008; 60(11):1307-1315.
34. Kim CK, Ghosh P and Rotello VM. Multimodal drug delivery using gold nanoparticles. Nanoscale. 2009; 1(1):61-67.
35. Lewinski N, Colvin V and Drezek R. Cytotoxicity of nanoparticles. Small. 2008; 4(1):26-49.
36. Jain KK. The role of nanobiotechnology in drug discovery. Advances in experimental medicine and biology. 2009; 655:37-43.
37. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R and Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature nanotechnology. 2007; 2(12):751-760.
38. Krol S. Challenges in drug delivery to the brain: Nature is against us. Journal of controlled release : official journal of the Controlled Release Society. 2012.
39. Jain KK. Role of nanobiotechnology in the personalized management of glioblastoma multiforme. Nanomedicine (Lond). 2011; 6(3):411-414.
40. Wankhede M, Bouras A, Kaluzova M and Hadjipanayis CG. Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy. Expert review of clinical pharmacology. 2012; 5(2):173-186.
41. Roger M, Clavreul A, Venier-Julienne MC, Passirani C, Montero-Menei C and Menei P. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials. 2011; 32(8):2106-2116.
42. Owens DE, 3rd and Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. International journal of pharmaceutics. 2006; 307(1):93-102.
43. Shan X, Yuan Y, Liu C, Tao X, Sheng Y and Xu F. Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles. Biomedical microdevices. 2009; 11(6):1187-1194.
44. Veiseh O, Gunn JW and Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Advanced drug delivery reviews. 2010; 62(3):284-304.
45. Sonavane G, Tomoda K and Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids and surfaces B, Biointerfaces. 2008; 66(2):274-280.
46. Gao K and Jiang X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. International journal of pharmaceutics. 2006; 310(1-2):213-219.
47. Pang Z, Gao H, Chen J, Shen S, Zhang B, Ren J, Guo L, Qian Y, Jiang X and Mei H. Intracellular delivery mechanism and brain delivery kinetics of biodegradable cationic bovine serum albumin-conjugated polymersomes. International journal of nanomedicine. 2012; 7:3421-3432.
48. Lu W, Wan J, Zhang Q, She Z and Jiang X. Aclarubicin-loaded cationic albumin-conjugated pegylated nanoparticle for glioma chemotherapy in rats. International journal of cancer Journal international du cancer. 2007; 120(2):420-431.
49. Bisgaier CL, Siebenkas MV and Williams KJ. Effects of apolipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes. The Journal of biological chemistry. 1989; 264(2):862-866.
50. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C and Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. Journal of drug targeting. 2002; 10(4):317-325.
51. Nicholson C and Sykova E. Extracellular space structure revealed by diffusion analysis. Trends in neurosciences. 1998; 21(5):207-215.
52. Ali MJ, Navalitloha Y, Vavra MW, Kang EW, Itskovich AC, Molnar P, Levy RM and Groothuis DR. Isolation of drug delivery from drug effect: problems of optimizing drug delivery parameters. Neuro-oncology. 2006; 8(2):109-118.
53. Navalitloha Y, Schwartz ES, Groothuis EN, Allen CV, Levy RM and Groothuis DR. Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors. Neuro-oncology. 2006; 8(3):227-233.
54. Allard E, Passirani C and Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials. 2009; 30(12):2302-2318.
55. Raghavan R, Brady ML, Rodriguez-Ponce MI, Hartlep A, Pedain C and Sampson JH. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurgical focus. 2006; 20(4):E12.
56. Vinchon-Petit S, Jarnet D, Paillard A, Benoit JP, Garcion E and Menei P. In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy. Journal of neuro-oncology. 2010; 97(2):195-205.
57. Allard E, Jarnet D, Vessieres A, Vinchon-Petit S, Jaouen G, Benoit JP and Passirani C. Local delivery of ferrociphenol lipid nanocapsules followed by external radiotherapy as a synergistic treatment against intracranial 9L glioma xenograft. Pharmaceutical research. 2010; 27(1):56-64.
58. Varenika V, Dickinson P, Bringas J, LeCouteur R, Higgins R, Park J, Fiandaca M, Berger M, Sampson J and Bankiewicz K. Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. Journal of neurosurgery. 2008; 109(5):874-880.
59. Sampson JH, Brady ML, Petry NA, Croteau D, Friedman AH, Friedman HS, Wong T, Bigner DD, Pastan I, Puri RK and Pedain C. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery. 2007; 60(2 Suppl 1):ONS89-98; discussion ONS98-89.
60. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advances in enzyme regulation. 2001; 41:189-207.
61. Maeda H, Bharate GY and Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2009; 71(3):409-419.
62. Maeda H, Wu J, Sawa T, Matsumura Y and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of controlled release : official journal of the Controlled Release Society. 2000; 65(1-2):271-284.
63. McBain SC, Yiu HH and Dobson J. Magnetic nanoparticles for gene and drug delivery. International journal of nanomedicine. 2008; 3(2):169-180.
64. Zhao M, Liang C, Li A, Chang J, Wang H, Yan R, Zhang J and Tai J. Magnetic paclitaxel nanoparticles inhibit glioma growth and improve the survival of rats bearing glioma xenografts. Anticancer research. 2010; 30(6):2217-2223.
65. Fang J, Nakamura H and Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced drug delivery reviews. 2011; 63(3):136-151.
66. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K, Wolter M, Sommerlad D, Henze AT, Nister M, Reifenberger G, Lundeberg J, Frisen J and Acker T. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain : a journal of neurology. 2010; 133(Pt 4):983-995.
67. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-760.
68. Koo YE, Reddy GR, Bhojani M, Schneider R, Philbert MA, Rehemtulla A, Ross BD and Kopelman R. Brain cancer diagnosis and therapy with nanoplatforms. Advanced drug delivery reviews. 2006; 58(14):1556-1577.
69. Bernardi RJ, Lowery AR, Thompson PA, Blaney SM and West JL. Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. Journal of neuro-oncology. 2008; 86(2):165-172.
70. Madhankumar AB, Slagle-Webb B, Wang X, Yang QX, Antonetti DA, Miller PA, Sheehan JM and Connor JR. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Molecular cancer therapeutics. 2009; 8(3):648-654.
71. Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, Liu L, Eyler CE, Heddleston JM, Wu Q, Minhas S, Soeda A, Hoeppner DJ, Ravin R, McKay RD, McLendon RE, et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell death & disease. 2011; 2:e200.
72. Wang CH, Chiou SH, Chou CP, Chen YC, Huang YJ and Peng CA. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine : nanotechnology, biology, and medicine. 2011; 7(1):69-79.
73. Frederick L, Wang XY, Eley G and James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer research. 2000; 60(5):1383-1387.
74. Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, Chen H, Wu X and Mao H. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer research. 2010; 70(15):6303-6312.
75. Lu W, Sun Q, Wan J, She Z and Jiang XG. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer research. 2006; 66(24):11878-11887.
76. Hall WA. Transferrin receptor on glioblastoma multiforme. Journal of neurosurgery. 1991; 74(2):313-314.
77. Kang C, Yuan X, Zhong Y, Pu P, Guo Y, Albadany A, Yu S, Zhang Z, Li Y, Chang J and Sheng J. Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles. Technology in cancer research & treatment. 2009; 8(1):61-70.
78. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO and Snyder EY. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(23):12846-12851.
79. Benedetti S, Pirola B, Pollo B, Magrassi L, Bruzzone MG, Rigamonti D, Galli R, Selleri S, Di Meco F, De Fraja C, Vescovi A, Cattaneo E and Finocchiaro G. Gene therapy of experimental brain tumors using neural progenitor cells. Nature medicine. 2000; 6(4):447-450.
80. Aboody K, Capela A, Niazi N, Stern JH and Temple S. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone. Neuron. 2011; 70(4):597-613.
81. Tyler MA, Ulasov IV, Sonabend AM, Nandi S, Han Y, Marler S, Roth J and Lesniak MS. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene therapy. 2009; 16(2):262-278.
82. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284(5411):143-147.
83. Beyer Nardi N and da Silva Meirelles L. Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handbook of experimental pharmacology. 2006; (174):249-282.
84. Erices A, Conget P and Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. British journal of haematology. 2000; 109(1):235-242.
85. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, Dragoo JL, Ashjian P, Thomas B, Benhaim P, Chen I, Fraser J and Hedrick MH. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells, tissues, organs. 2003; 174(3):101-109.
86. Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW and Gimble JM. Surface protein characterization of human adipose tissue-derived stromal cells. Journal of cellular physiology. 2001; 189(1):54-63.
87. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I and Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood. 2001; 98(8):2396-2402.
88. Tsai MS, Lee JL, Chang YJ and Hwang SM. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod. 2004; 19(6):1450-1456.
89. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M and Lang FF. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer research. 2005; 65(8):3307-3318.
90. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y and Hamada H. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene therapy. 2004; 11(14):1155-1164.
91. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ and Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer research. 2002; 62(13):3603-3608.
92. Wu X, Hu J, Zhou L, Mao Y, Yang B, Gao L, Xie R, Xu F, Zhang D, Liu J and Zhu J. In vivo tracking of superparamagnetic iron oxide nanoparticle-labeled mesenchymal stem cell tropism to malignant gliomas using magnetic resonance imaging. Laboratory investigation. Journal of neurosurgery. 2008; 108(2):320-329.
93. Ryu CH, Park KY, Kim SM, Jeong CH, Woo JS, Hou Y and Jeun SS. Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma. Biochemical and biophysical research communications. 2012; 421(3):585-590.
94. Kosaka H, Ichikawa T, Kurozumi K, Kambara H, Inoue S, Maruo T, Nakamura K, Hamada H and Date I. Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma. Cancer gene therapy. 2012; 19(8):572-578.
95. Thiele L, Merkle HP and Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharmaceutical research. 2003; 20(2):221-228.
96. Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ, Caplice N and Russell SJ. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Molecular therapy : the journal of the American Society of Gene Therapy. 2007; 15(1):114-122.
97. Thorne SH, Negrin RS and Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science. 2006; 311(5768):1780-1784.
98. Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Vile RG and Melcher AA. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene therapy. 2009; 16(5):689-699.
99. Qiao J, Kottke T, Willmon C, Galivo F, Wongthida P, Diaz RM, Thompson J, Ryno P, Barber GN, Chester J, Selby P, Harrington K, Melcher A and Vile RG. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nature medicine. 2008; 14(1):37-44.
100. Imitola J, Raddassi K, Park KI, Mueller FJ, Nieto M, Teng YD, Frenkel D, Li J, Sidman RL, Walsh CA, Snyder EY and Khoury SJ. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(52):18117-18122.
101. Zhao D, Najbauer J, Garcia E, Metz MZ, Gutova M, Glackin CA, Kim SU and Aboody KS. Neural stem cell tropism to glioma: critical role of tumor hypoxia. Molecular cancer research : MCR. 2008; 6(12):1819-1829.
102. Jones BJ and McTaggart SJ. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Experimental hematology. 2008; 36(6):733-741.
103. Nativo P, Prior IA and Brust M. Uptake and intracellular fate of surface-modified gold nanoparticles. ACS nano. 2008; 2(8):1639-1644.
104. Le Bihan O, Bonnafous P, Marak L, Bickel T, Trepout S, Mornet S, De Haas F, Talbot H, Taveau JC and Lambert O. Cryo-electron tomography of nanoparticle transmigration into liposome. Journal of structural biology. 2009; 168(3):419-425.
105. Ekkapongpisit M, Giovia A, Follo C, Caputo G and Isidoro C. Biocompatibility, endocytosis, and intracellular trafficking of mesoporous silica and polystyrene nanoparticles in ovarian cancer cells: effects of size and surface charge groups. International journal of nanomedicine. 2012; 7:4147-4158.
106. Panyam J, Zhou WZ, Prabha S, Sahoo SK and Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2002; 16(10):1217-1226.
107. Paillard A, Hindre F, Vignes-Colombeix C, Benoit JP and Garcion E. The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials. 2010; 31(29):7542-7554.
108. Lévesque M, Neuman T and Rezak M. Therapeutic Microinjection of Autologous Adult Human Neural Stem Cells and Differentiated Neurons for Parkinson's Disease: Five-Year Post-Operative Outcome. The Open Stem Cell Journal. 2009; (1):20-29.
109. Danielyan L, Schafer R, von Ameln-Mayerhofer A, Bernhard F, Verleysdonk S, Buadze M, Lourhmati A, Klopfer T, Schaumann F, Schmid B, Koehle C, Proksch B, Weissert R, Reichardt HM, van den Brandt J, Buniatian GH, et al. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation research. 2011; 14(1):3-16.
110. van Velthoven CT, Kavelaars A, van Bel F and Heijnen CJ. Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. Pediatric research. 2010; 68(5):419-422.
111. Reitz M, Demestre M, Sedlacik J, Meissner H, Fiehler J, Kim SU, Westphal M and Schmidt NO. Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma. Stem cells translational medicine. 2012; 1(12):866-873.
112. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH and Bang OY. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010; 28(6):1099-1106.
113. Bang OY, Lee JS, Lee PH and Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Annals of neurology. 2005; 57(6):874-882.
114. Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S, Onodera R, Waxman SG and Kocsis JD. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain : a journal of neurology. 2011; 134(Pt 6):1790-1807.
115. Caplan AI and Bruder SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends in molecular medicine. 2001; 7(6):259-264.
116. Everts M, Saini V, Leddon JL, Kok RJ, Stoff-Khalili M, Preuss MA, Millican CL, Perkins G, Brown JM, Bagaria H, Nikles DE, Johnson DT, Zharov VP and Curiel DT. Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. Nano letters. 2006; 6(4):587-591.
117. Park JS, Na K, Woo DG, Yang HN, Kim JM, Kim JH, Chung HM and Park KH. Non-viral gene delivery of DNA polyplexed with nanoparticles transfected into human mesenchymal stem cells. Biomaterials. 2010; 31(1):124-132.
118. Park JS, Yang HN, Woo DG, Jeon SY, Do HJ, Lim HY, Kim JH and Park KH. Chondrogenesis of human mesenchymal stem cells mediated by the combination of SOX trio SOX5, 6, and 9 genes complexed with PEI-modified PLGA nanoparticles. Biomaterials. 2011; 32(14):3679-3688.
119. Yang F, Cho SW, Son SM, Bogatyrev SR, Singh D, Green JJ, Mei Y, Park S, Bhang SH, Kim BS, Langer R and Anderson DG. Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(8):3317-3322.
120. Cromer Berman SM, Walczak P and Bulte JW. Tracking stem cells using magnetic nanoparticles. Wiley interdisciplinary reviews Nanomedicine and nanobiotechnology. 2011; 3(4):343-355.
121. Flexman JA, Cross DJ, Tran LN, Sasaki T, Kim Y and Minoshima S. Quantitative analysis of neural stem cell migration and tracer clearance in the rat brain by MRI. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging. 2011; 13(1):104-111.
122. Menon LG, Pratt J, Yang HW, Black PM, Sorensen GA and Carroll RS. Imaging of human mesenchymal stromal cells: homing to human brain tumors. Journal of neuro-oncology. 2012; 107(2):257-267.
123. Thu MS, Najbauer J, Kendall SE, Harutyunyan I, Sangalang N, Gutova M, Metz MZ, Garcia E, Frank RT, Kim SU, Moats RA and Aboody KS. Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PloS one. 2009; 4(9):e7218.
124. Li L, Guan Y, Liu H, Hao N, Liu T, Meng X, Fu C, Li Y, Qu Q, Zhang Y, Ji S, Chen L, Chen D and Tang F. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. ACS nano. 2011; 5(9):7462-7470.
125. Roger M, Clavreul A, Huynh NT, Passirani C, Schiller P, Vessieres A, Montero-Menei C and Menei P. Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. International journal of pharmaceutics. 2012; 423(1):63-68.
126. Rachakatla RS, Balivada S, Seo GM, Myers CB, Wang H, Samarakoon TN, Dani R, Pyle M, Kroh FO, Walker B, Leaym X, Koper OB, Chikan V, Bossmann SH, Tamura M and Troyer DL. Attenuation of mouse melanoma by A/C magnetic field after delivery of bi-magnetic nanoparticles by neural progenitor cells. ACS nano. 2010; 4(12):7093-7104.
127. Chung TH, Hsiao JK, Hsu SC, Yao M, Chen YC, Wang SW, Kuo MY, Yang CS and Huang DM. Iron oxide nanoparticle-induced epidermal growth factor receptor expression in human stem cells for tumor therapy. ACS nano. 2011; 5(12):9807-9816.
128. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell. 2010; 17(1):98-110.
129. Chien LY, Hsiao JK, Hsu SC, Yao M, Lu CW, Liu HM, Chen YC, Yang CS and Huang DM. In vivo magnetic resonance imaging of cell tropism, trafficking mechanism, and therapeutic impact of human mesenchymal stem cells in a murine glioma model. Biomaterials. 2011; 32(12):3275-3284.
130. Pan Y, Neuss S, Leifert A, Fischler M, Wen F, Simon U, Schmid G, Brandau W and Jahnen-Dechent W. Size-dependent cytotoxicity of gold nanoparticles. Small. 2007; 3(11):1941-1949.
131. Sargent LM, Shvedova AA, Hubbs AF, Salisbury JL, Benkovic SA, Kashon ML, Lowry DT, Murray AR, Kisin ER, Friend S, McKinstry KT, Battelli L and Reynolds SH. Induction of aneuploidy by single-walled carbon nanotubes. Environmental and molecular mutagenesis. 2009; 50(8):708-717.
132. Monteiller C, Tran L, MacNee W, Faux S, Jones A, Miller B and Donaldson K. The pro-inflammatory effects of low-toxicity low-solubility particles, nanoparticles and fine particles, on epithelial cells in vitro: the role of surface area. Occupational and environmental medicine. 2007; 64(9):609-615.
133. Vallhov H, Qin J, Johansson SM, Ahlborg N, Muhammed MA, Scheynius A and Gabrielsson S. The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. Nano letters. 2006; 6(8):1682-1686.
134. Kagan VE, Tyurina YY, Tyurin VA, Konduru NV, Potapovich AI, Osipov AN, Kisin ER, Schwegler-Berry D, Mercer R, Castranova V and Shvedova AA. Direct and indirect effects of single walled carbon nanotubes on RAW 264.7 macrophages: role of iron. Toxicology letters. 2006; 165(1):88-100.
135. Suh WH, Suslick KS, Stucky GD and Suh YH. Nanotechnology, nanotoxicology, and neuroscience. Progress in neurobiology. 2009; 87(3):133-170.
136. Sheng WY and Huang L. Cancer immunotherapy and nanomedicine. Pharmaceutical research. 2011; 28(2):200-214.
137. Zolnik BS, Stern ST, Kaiser JM, Heakal Y, Clogston JD, Kester M and McNeil SE. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug metabolism and disposition: the biological fate of chemicals. 2008; 36(8):1709-1715.
138. Zolnik BS and Sadrieh N. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Advanced drug delivery reviews. 2009; 61(6):422-427.
139. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD and Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998; 16(7):2445-2451.
140. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L and Tendler C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2004; 15(3):440-449.
141. Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M and Marini FC. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer research. 2007; 67(24):11687-11695.
142. Kendall SE, Najbauer J, Johnston HF, Metz MZ, Li S, Bowers M, Garcia E, Kim SU, Barish ME, Aboody KS and Glackin CA. Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling. Stem Cells. 2008; 26(6):1575-1586.
143. Kadiu I, Nowacek A, McMillan J and Gendelman HE. Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond). 2011; 6(6):975-994.
144. Greulich C, Diendorf J, Simon T, Eggeler G, Epple M and Koller M. Uptake and intracellular distribution of silver nanoparticles in human mesenchymal stem cells. Acta biomaterialia. 2011; 7(1):347-354.
145. Lee CH, Cheng SH, Huang IP, Souris JS, Yang CS, Mou CY and Lo LW. Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics. Angew Chem Int Ed Engl. 2010; 49(44):8214-8219.
146. Fang C, Kievit FM, Veiseh O, Stephen ZR, Wang T, Lee D, Ellenbogen RG and Zhang M. Fabrication of magnetic nanoparticles with controllable drug loading and release through a simple assembly approach. Journal of controlled release : official journal of the Controlled Release Society. 2012; 162(1):233-241.
147. Cui Y, Dong H, Cai X, Wang D and Li Y. Mesoporous Silica Nanoparticles Capped with Disulfide-Linked PEG Gatekeepers for Glutathione-Mediated Controlled Release. ACS applied materials & interfaces. 2012.
148. Aschkenasy C and Kost J. On-demand release by ultrasound from osmotically swollen hydrophobic matrices. Journal of controlled release : official journal of the Controlled Release Society. 2005; 110(1):58-66.
149. Yuan Q, Zhang Y, Chen T, Lu D, Zhao Z, Zhang X, Li Z, Yan CH and Tan W. Photon-manipulated drug release from a mesoporous nanocontainer controlled by azobenzene-modified nucleic acid. ACS nano. 2012; 6(7):6337-6344.
150. You J, Zhang R, Xiong C, Zhong M, Melancon M, Gupta S, Nick AM, Sood AK and Li C. Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer research. 2012; 72(18):4777-4786.
151. Lammers T, Peschke P, Kuhnlein R, Subr V, Ulbrich K, Debus J, Huber P, Hennink W and Storm G. Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. Journal of controlled release : official journal of the Controlled Release Society. 2007; 117(3):333-341.
152. Ubiali F, Nava S, Nessi V, Frigerio S, Parati E, Bernasconi P, Mantegazza R and Baggi F. Allorecognition of human neural stem cells by peripheral blood lymphocytes despite low expression of MHC molecules: role of TGF-beta in modulating proliferation. International immunology. 2007; 19(9):1063-1074.
153. Krystkowiak P, Gaura V, Labalette M, Rialland A, Remy P, Peschanski M and Bachoud-Levi AC. Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease. PloS one. 2007; 2(1):e166.
154. Ernst N, Tiede S, Tronnier V, Kruse C, Zechel C and Paus R. An improved, standardised protocol for the isolation, enrichment and targeted neural differentiation of Nestin+ progenitors from adult human dermis. Experimental dermatology. 2010; 19(6):549-555.
155. Mitrecic D, Gajovic S and Pochet R. Toward the treatments with neural stem cells: experiences from amyotrophic lateral sclerosis. Anat Rec (Hoboken). 2009; 292(12):1962-1967.
156. Qian ZM, Li H, Sun H and Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacological reviews. 2002; 54(4):561-587.
157. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Vile RG, Uster PS, Peters AM and Stewart JS. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000; 6(12):4939-4949.
158. Harrington KJ, Rowlinson-Busza G, Uster PS and Stewart JS. Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours. Cancer chemotherapy and pharmacology. 2000; 46(1):10-18.